Case Report - Case Report - Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy

Sep 23, 2026

Uploaded by Mimi

Case report describes a rare synchronous multiple primary cancer presentation involving lung adenocarcinoma with bone metastasis, gastric signet-ring cell carcinoma, and rectal cancer in a 64-year-old male. After multidisciplinary team consultation, systemic therapy with sintilimab combined with oxaliplatin and capecitabine was started while furmonertinib targeted therapy continued. After six cycles, lung lesions showed marked reduction and gastric and intestinal tumors remained stable. Maintenance treatment achieved sustained disease control without severe adverse effects, supporting integrated immunotherapy and chemotherapy and the need for individualized biomarker-driven strategies.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

1 Introduction

2 Case summary

TYPE Case Report PUBLISHED 05 August 2025 DOI 10.3389/fimmu.2025.1614911 OPEN ACCESS EDITED BY Antonio Lax, University of Murcia, Spain REVIEWED BY Thomas Böldicke, Helmholtz Association of German Research Centers (HZ), Germany U˘gur ahin, Ankara University, Türkiye *CORRESPONDENCE Zheng-Quan Feng [fzhq213@aliyun.com](fzhq213@aliyun.com) †These authors have contributed equally to this work RECEIVED 20 April 2025 ACCEPTED 21 July 2025 PUBLISHED 05 August 2025 CITATION Zhang Q-Q, Luo X-X, Chen H, Wang W, Xie Y-F, Qiao H-L, Miao H-J and Feng Z-Q (2025) Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy. Front. Immunol. 16:1614911 . doi: 10.3389/fimmu.2025.1614911 COPYRIGHT © 2025 Zhang, Luo, Chen, Wang, Xie, Qiao, Miao and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy Qi-Qing Zhang 1†, Xin-Xin Luo 2†, Hua Chen 1, Wei Wang 3, Yi-Fan Xie3, Hong-Li Qiao 1, Hao-Jun Miao 1 and Zheng-Quan Feng 1* 1 Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China, 2College of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, 3 Department of Pathology, Tongde Hospital of Zhejiang Province, Hangzhou, China This case report presents a rare instance of synchronous multiple primary cancers involving lung adenocarcinoma with bone metastasis, gastric signetring cell carcinoma, and rectal cancer. The 64-year-old male patient was treated with a combination of sintilimab, chemotherapy, and targeted therapy. Following a multidisciplinary team consultation, systemic treatment with sintilimab, oxaliplatin, and capecitabine was initiated concurrently while furmonertinib targeted therapy continued. After six cycles, the lung lesions showed signiﬁcant reduction, while the gastric and intestinal tumors remained stable. The patient transitioned to maintenance therapy and achieved sustained disease control without severe adverse effects. This case highlights the potential of an integrated immunotherapy and chemotherapy approach for treating multiple primary malignancies with distinct [pathological origins. report](pathological origins. report) also underscores the need for individualized, biomarker-driven treatment strategies and further research on optimal therapeutic combinations for synchronous multiple primary cancers. KEYWORDS chemotherapy, immunotherapy, multiple primary cancers, sintilimab, targeted therapy 1 Introduction Multiple primary cancers—also known as compound or repeated cancers—refer to the occurrence of two or more independent primary cancers in the same individual, either simultaneously or sequentially. Based on the time interval between occurrences, they are classiﬁed as metachronous or synchronous multiple primary cancers (1). Multiple primary Frontiers in Immunology 01 [frontiersin.org](frontiersin.org) cancers are deﬁned according to guidelines from the Surveillance Epidemiology and End Results (SEER) Program and the International Association of Cancer Registries (IACR) along with the International Agency for Research on Cancer (IARC) (2–4) . The incidence of multiple primary cancers in the cancer population ranges from 2.4–8%, and can reach as high as 17% after 20 years of follow-up (5) . Currentl

FAQs

What condition does the case report describe?

It reports a rare synchronous multiple primary cancers case involving lung adenocarcinoma with bone metastasis, gastric signet-ring cell carcinoma, and rectal cancer.

Which treatment regimen was used and how was it initiated?

The patient received sintilimab with chemotherapy (oxaliplatin and capecitabine) while furmonertinib targeted therapy was continued, initiated concurrently after a multidisciplinary team consultation.

What were the treatment outcomes after six cycles?

After six cycles, lung lesions showed significant reduction, while gastric and intestinal tumors remained stable, followed by maintenance therapy for sustained disease control without severe adverse effects.

Sep 23, 2026

Uploaded by Mimi